Manni R, Ratti M T, Perucca E, Galimberti C A, Tartara A
Istituto Neurologico C. Mondino, Pavia, Italy.
Electroencephalogr Clin Neurophysiol. 1993 May;86(5):322-8. doi: 10.1016/0013-4694(93)90044-v.
Subjective and objective measures of daytime sleepiness and psychomotor function were determined in normal control subjects and in epileptic patients on chronic monotherapy with phenobarbital or valproate (n = 10 in each group). All patients had primary generalized epilepsy with a normal resting EEG and were seizure-free for at least 1 year. After nocturnal polysomnographic recording, each subject was evaluated at 2 h intervals between 10:00 and 16:00 h by using multiple sleep latency tests (MSLT), a visual analogue rating scale for alertness (VARS), an anxiety scale (STAI-X1) and a battery of psychomotor tests. Nocturnal sleep parameters before daytime assessment were comparable in the 3 groups. At MSLT, patients on phenobarbital showed a shorter mean sleep latency (9.0 +/- 1.7 min) compared with the valproate group (12.5 +/- 1.3 min) and controls (12.9 +/- 1.2 min), though within-group variability was considerable. Compared with controls, patients on phenobarbital showed longer motor movement times, impaired attention (cancellation test, CT), reduced processing speed (digit-symbol substitution, DSS) and a trend towards lower critical flicker fusion threshold. Patients on valproate showed some impairment in attention and a trend towards longer motor movement time. In patients, no correlation was found between assessed parameters and serum drug concentrations, which were 19.3 +/- 1.7 micrograms/ml for phenobarbital and 85.7 +/- 4.7 micrograms/ml for valproic acid.
在正常对照受试者以及接受苯巴比妥或丙戊酸盐长期单一疗法的癫痫患者(每组n = 10)中,测定了白天嗜睡和精神运动功能的主观及客观指标。所有患者均患有原发性全身性癫痫,静息脑电图正常,且至少1年无癫痫发作。在进行夜间多导睡眠图记录后,于上午10:00至下午16:00之间每隔2小时,通过多次睡眠潜伏期测试(MSLT)、警觉性视觉模拟评分量表(VARS)、焦虑量表(STAI-X1)以及一系列精神运动测试对每位受试者进行评估。白天评估前的夜间睡眠参数在3组中具有可比性。在MSLT测试中,服用苯巴比妥的患者平均睡眠潜伏期较短(9.0±1.7分钟),而丙戊酸盐组(12.5±1.3分钟)和对照组(12.9±1.2分钟)较长,不过组内变异性较大。与对照组相比,服用苯巴比妥的患者运动动作时间更长、注意力受损(划消试验,CT)、处理速度降低(数字符号替换,DSS),且临界闪烁融合阈值有降低趋势。服用丙戊酸盐的患者在注意力方面有一定损害,运动动作时间有延长趋势。在患者中,未发现评估参数与血清药物浓度之间存在相关性,苯巴比妥的血清药物浓度为19.3±1.7微克/毫升,丙戊酸为85.7±4.7微克/毫升。